Therapeutic Response

Wild type KRAS and Wild type NRAS status confers therapeutic sensitivity to Fluorouracil in combination with Oxaliplatin and Panitumumab in patients with Colorectal Adenocarcinoma.

Statements

Source and description

Vectibix (panitumumab) [product information]. EMA. The European Medicines Agency (EMA) has authorized panitumumab in combination with FOLFOX or FOLFIRI for the first-line treatment of adult patients with wild-type RAS metastatic colorectal cancer (mCRPC). Panitumumab's product information further states that evidence of wild-type RAS (KRAS and NRAS) status is required before initiating treatment with panitumumab and that mutational status should be deteremined by an experienced laboratory using validated test methods for detection of KRAS (exons 2, 3, and 4) and NRAS (exons 2, 3, and 4) variants.